

VIII. Claims

What is Claimed:

1. A method of improving cognitive function in a subject diagnosed with an age-related cognitive disease, the method comprising administering a therapeutically effective amount of an LTA4H modulatory agent.
2. The method of claim 1 wherein the cognitive disease is from the group consisting of Alzheimer's Disease, mild cognitive impairment, Parkinson's Disease, Parkinsonism, Frontotemporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, multiple sclerosis, dementia, dementia with Lewy bodies, and progressive supranuclear palsy.
3. The method of claim 1 wherein the LTA4H modulatory agent is a small organic molecule antagonist to LTA4H.
4. The method of claim 1 wherein the LTA4H modulatory agent is an antibody to LTA4H.
5. The method of claim 3 wherein the antagonist to LTA4H antagonizes the epoxide hydrolase activity of LTA4H.
6. The method of claim 3 wherein the antagonist to LTA4H antagonizes both the epoxide hydrolase activity and the aminopeptidase activity of LTA4H.
7. The method of any of the preceding claims wherein the subject is a mammal.
8. The method of claim 7 wherein the mammal is a human.
9. A kit for use in improving cognitive function in a subject diagnosed with an age-related cognitive disease, the kit comprising an LTA4H modulatory agent.
10. The kit of claim 9 wherein the LTA4H modulatory agent is a small organic molecule antagonist to LTA4H.
11. The kit of claim 9 wherein the LTA4H modulatory agent is an antibody to LTA4H.
12. The kit of claim 11 wherein the antagonist to LTA4H antagonizes the epoxide hydrolase activity of LTA4H.
13. The kit of claim 12 wherein the antagonist to LTA4H antagonizes both the epoxide hydrolase activity and the aminopeptidase activity of LTA4H.